3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial

Lancet

Volumn 351, Issue 9110, 1998, Pages 1180-1181

  Andersson, B ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

METOPROLOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART DILATATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032542884     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79125-X     Document Type: Article

References (5)

1. 1 Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-46.
2. 2 Andersson B, Lomsky M, Waagstein F. The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. Eur Heart J 1993; 14: 1375-85.
3. 3 Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24: 1310-20.
4. 4 Andersson B, Caidahl K, Di Lenarda A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94: 673-82.
5. 5 The International Steering Committee on behalf of the MERIT-HF Study Group. Rationale, design, and organization of the Metoprolol CR/XL randomised Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997; 80: 54-58J.